Cardinal Health, US14149Y1082

Cardinal Health stock faces Class I recall for infusion kits

Published on 11/18/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Cardinal Health stock faces a Class I recall involving Presource procedure kits with recalled BD Alaris infusion sets. Customers were told to quarantine them.

FDA raises recall severity

  • The FDA classified Cardinal Health's correction of Presource procedure kits as a Class I recall.
  • The affected kits contain recalled BD Alaris pump infusion sets that can cause under-infusion, over-infusion or failure to infuse.
  • Cardinal Health instructed customers to quarantine the kits and remove and discard the affected sets.
Cardinal Health, US14149Y1082, Illustration mit AI erstellt.

On November 16, the US Food and Drug Administration raised the severity classification for Cardinal Health's correction of Presource procedure kits containing recalled BD Alaris pump infusion sets, Medical Week Daily reported on Wednesday, citing the FDA's MedWatch alert.

Recall affects hospital procedure kits

The FDA classified the action as Class I, its most serious recall category. The affected Presource kits contain BD Alaris pump infusion sets. According to the report, the sets can cause under-infusion, over-infusion or failure to infuse, creating a potential patient-safety risk when the components are used during hospital procedures.

Cardinal Health has told customers to quarantine the kits and remove and discard the recalled infusion sets. The report said the correction covers kits used in settings including labor, pediatric angiography and cardiac procedures. As of August 19, BD had reported no serious injuries or deaths linked to the issue, according to the FDA information cited in the report.

Investor focus turns to execution

The regulatory action adds a quality and execution issue to Cardinal Health's medical-products operations. Investors will likely watch the scope of the affected inventory, customer communication and any financial impact as the company handles the correction. The development also matters for hospital relationships, where product reliability and timely replacement are central to supply contracts.

Cardinal Health stock traded at 253.60 euros on Lang & Schwarz at 13:10 CET on Wednesday, November 18.

Cardinal Health at a glance

  • Company: Cardinal Health, Inc.
  • ISIN: US14149Y1082
  • Ticker: CAH
  • Primary exchange: New York Stock Exchange
  • Lang & Schwarz quote: 253.60 euros at 13:10 CET on November 18, 2026

The S&P 500 provides the broader US equity backdrop for Cardinal Health stock.

More news and analyses on Cardinal Health stock

Disclaimer...
en | US14149Y1082 | CARDINAL HEALTH | boerse | 70530857 | bgmi